1.68
price down icon5.11%   -0.0904
pre-market  Pre-market:  1.64   -0.04   -2.38%
loading
Galmed Pharmaceuticals Ltd stock is traded at $1.68, with a volume of 13,170. It is down -5.11% in the last 24 hours and down -33.33% over the past month. Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
See More
Previous Close:
$1.7704
Open:
$1.78
24h Volume:
13,170
Relative Volume:
0.43
Market Cap:
$2.78M
Revenue:
-
Net Income/Loss:
$-6.91M
P/E Ratio:
-0.5153
EPS:
-3.26
Net Cash Flow:
$-6.14M
1W Performance:
-12.04%
1M Performance:
-33.33%
6M Performance:
-59.12%
1Y Performance:
-61.06%
1-Day Range:
Value
$1.68
$1.79
1-Week Range:
Value
$1.68
$2.09
52-Week Range:
Value
$1.68
$23.80

Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile

Name
Name
Galmed Pharmaceuticals Ltd
Name
Phone
-
Name
Address
-
Name
Employee
8
Name
Twitter
@GalmedPharma
Name
Next Earnings Date
2024-11-20
Name
Latest SEC Filings
Name
GLMD's Discussions on Twitter

Compare GLMD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GLMD
Galmed Pharmaceuticals Ltd
1.68 2.78M 0 -6.91M -6.14M -3.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades

Date Action Analyst Rating Change
May-22-20 Downgrade B. Riley FBR Buy → Neutral
Feb-04-20 Initiated Craig Hallum Buy
Jan-30-20 Resumed Cantor Fitzgerald Overweight
Dec-02-19 Initiated Canaccord Genuity Buy
Dec-12-18 Initiated B. Riley FBR Buy
Aug-02-18 Reiterated Maxim Group Buy
Jul-13-18 Initiated Stifel Buy
Jul-12-18 Initiated Cantor Fitzgerald Overweight
Jun-12-18 Reiterated H.C. Wainwright Buy
Mar-15-18 Upgrade Maxim Group Hold → Buy
Feb-14-18 Downgrade Maxim Group Buy → Hold
Feb-12-18 Reiterated H.C. Wainwright Buy
Nov-15-17 Initiated ROTH Capital Buy
Aug-08-17 Reiterated H.C. Wainwright Buy
Jul-31-17 Reiterated Maxim Group Buy
Aug-01-16 Reiterated Maxim Group Buy
Jul-06-16 Resumed ROTH Capital Buy
Mar-28-16 Resumed H.C. Wainwright Buy
Jun-23-15 Initiated H.C. Wainwright Buy
May-06-15 Initiated Sun Trust Rbsn Humphrey Buy
View All

Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News

pulisher
Mar 13, 2025

Galmed Phar stock hits 52-week low at $1.75 amid challenges - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Galmed Phar stock hits 52-week low at $1.75 amid challenges By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com - Defense World

Mar 12, 2025
pulisher
Feb 28, 2025

Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 27, 2025

Galmed Phar stock hits 52-week low at $2.21 amid challenges - Investing.com Australia

Feb 27, 2025
pulisher
Feb 26, 2025

Galmed Phar stock hits 52-week low at $2.21 amid challenges By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 24, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World

Feb 24, 2025
pulisher
Feb 17, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com - Defense World

Feb 17, 2025
pulisher
Feb 08, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com - Defense World

Feb 08, 2025
pulisher
Jan 31, 2025

StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World

Jan 31, 2025
pulisher
Dec 05, 2024

Galmed Phar stock hits 52-week low at $2.6 amid market challenges - Investing.com Nigeria

Dec 05, 2024
pulisher
Dec 05, 2024

Galmed Phar stock hits 52-week low at $2.6 amid market challenges By Investing.com - Investing.com South Africa

Dec 05, 2024
pulisher
Nov 26, 2024

Galmed Phar stock hits 52-week low at $2.71 amid market challenges By Investing.com - Investing.com South Africa

Nov 26, 2024
pulisher
Nov 26, 2024

Galmed Phar stock hits 52-week low at $2.71 amid market challenges - Investing.com Nigeria

Nov 26, 2024
pulisher
Nov 16, 2024

Galmed Pharmaceuticals: Q3 Earnings Snapshot - New Haven Register

Nov 16, 2024
pulisher
Nov 14, 2024

Galmed Pharmaceuticals Embraces Market with New Sales Agreement - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024
pulisher
Nov 12, 2024

Galmed Phar stock hits 52-week low at $2.73 amid challenges - Investing.com Australia

Nov 12, 2024
pulisher
Nov 11, 2024

500: Something went wrong - Investing.com Canada

Nov 11, 2024
pulisher
Oct 21, 2024

Galmed Pharmaceuticals Amends Equity Purchase Agreement - TipRanks

Oct 21, 2024
pulisher
Oct 11, 2024

Acyl CoA Desaturase Market Current Status and Future Prospects - IndiaPolitics.com

Oct 11, 2024
pulisher
Oct 04, 2024

galmed pharmaceuticals ltd. Earnings dates - RTTNews

Oct 04, 2024
pulisher
Oct 02, 2024

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank? - Benzinga

Oct 02, 2024
pulisher
Oct 01, 2024

Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Above 50-Day Moving Average of $4.52 - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

United States shares lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN

Oct 01, 2024
pulisher
Sep 26, 2024

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN

Sep 26, 2024
pulisher
Sep 26, 2024

(GLMD) Long Term Investment Analysis - Stock Traders Daily

Sep 26, 2024
pulisher
Sep 26, 2024

Galmed reports positive results for Aramchol in NASH study By Investing.com - Investing.com Australia

Sep 26, 2024
pulisher
Sep 25, 2024

Galmed reports positive results for Aramchol in NASH study - Investing.com India

Sep 25, 2024
pulisher
Sep 25, 2024

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PR Newswire

Sep 25, 2024
pulisher
Sep 25, 2024

Post-Trade Analysis: Galmed Pharmaceuticals Ltd (GLMD) Slides -13.90, Closing at 8.05 - The Dwinnex

Sep 25, 2024
pulisher
Sep 24, 2024

Take off with Galmed Pharmaceuticals Ltd (GLMD): Get ready for trading - SETE News

Sep 24, 2024
pulisher
Sep 23, 2024

Understanding GLMD stock ratios for better investment decisions - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

GLMD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Sep 23, 2024
pulisher
Sep 23, 2024

Optimistic Market Report Drives Galmed Pharmaceuticals (GLMD) Stock Upward - Stocks Telegraph

Sep 23, 2024
pulisher
Sep 20, 2024

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs - GlobeNewswire

Sep 20, 2024

Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):